Inhibition of Protein Prenylation of GTPases Alters Endothelial Barrier Function.
Rac1
RhoA
adherens junctions
endothelial permeability
geranylgeranyl transferase
peripheral actin
statins
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
18 Dec 2019
18 Dec 2019
Historique:
received:
29
10
2019
revised:
13
12
2019
accepted:
15
12
2019
entrez:
22
12
2019
pubmed:
22
12
2019
medline:
6
5
2020
Statut:
epublish
Résumé
The members of Rho family of GTPases, RhoA and Rac1 regulate endothelial cytoskeleton dynamics and hence barrier integrity. The spatial activities of these GTPases are regulated by post-translational prenylation. In the present study, we investigated the effect of prenylation inhibition on the endothelial cytoskeleton and barrier properties. The study was carried out in human umbilical vein endothelial cells (HUVEC) and protein prenylation is manipulated with various pharmacological inhibitors. Inhibition of either complete prenylation using statins or specifically geranylgeranylation but not farnesylation has a biphasic effect on HUVEC cytoskeleton and permeability. Short-term treatment inhibits the spatial activity of RhoA/Rho kinase (Rock) to actin cytoskeleton resulting in adherens junctions (AJ) stabilization and ameliorates thrombin-induced barrier disruption whereas long-term inhibition results in collapse of endothelial cytoskeleton leading to increased basal permeability. These effects are reversed by supplementing the cells with geranylgeranyl but not farnesyl pyrophosphate. Moreover, long-term inhibition of protein prenylation results in basal hyper activation of RhoA/Rock signaling that is antagonized by a specific Rock inhibitor or an activation of cAMP signaling. In conclusion, inhibition of geranylgeranylation in endothelial cells (ECs) exerts biphasic effect on endothelial barrier properties. Short-term inhibition stabilizes AJs and hence barrier function whereas long-term treatment results in disruption of barrier properties.
Identifiants
pubmed: 31861297
pii: ijms21010002
doi: 10.3390/ijms21010002
pmc: PMC6981884
pii:
doi:
Substances chimiques
rho-Associated Kinases
EC 2.7.11.1
GTP Phosphohydrolases
EC 3.6.1.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Justus Liebig Universität Gießen
ID : 62589122
Références
Clin Exp Metastasis. 2003;20(6):561-7
pubmed: 14598891
J Cell Physiol. 1998 Jul;176(1):150-65
pubmed: 9618155
Am J Physiol Lung Cell Mol Physiol. 2005 Jun;288(6):L1026-32
pubmed: 15665042
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Oncogene. 2018 Feb 15;37(7):847-860
pubmed: 29059167
Vascul Pharmacol. 2002 Nov;39(4-5):187-99
pubmed: 12747959
ACS Chem Biol. 2015 Jan 16;10(1):51-62
pubmed: 25402849
Arterioscler Thromb Vasc Biol. 2012 Aug;32(8):e90-102
pubmed: 22723439
J Biol Chem. 2008 Sep 12;283(37):25150-63
pubmed: 18614539
Nat Rev Mol Cell Biol. 2016 Feb;17(2):110-22
pubmed: 26790532
J Cell Sci. 2008 Jul 1;121(Pt 13):2115-22
pubmed: 18565824
Am J Physiol Lung Cell Mol Physiol. 2006 Jun;290(6):L1173-82
pubmed: 16428270
Am J Cardiovasc Drugs. 2008;8(6):373-418
pubmed: 19159124
Circulation. 2000 Dec 5;102(23):2803-9
pubmed: 11104736
J Bone Miner Res. 2006 May;21(5):684-94
pubmed: 16734383
Physiol Rep. 2014 Oct 24;2(10):null
pubmed: 25344477
Eur Respir J. 2006 May;27(5):1026-32
pubmed: 16707397
Proc Soc Exp Biol Med. 1991 Mar;196(3):338-43
pubmed: 1998010
J Cell Sci. 2001 Apr;114(Pt 7):1343-55
pubmed: 11257000
Nat Rev Drug Discov. 2007 Jul;6(7):541-55
pubmed: 17585331
Tissue Barriers. 2016 Aug 25;4(4):e1228439
pubmed: 28123925
Am J Respir Cell Mol Biol. 2004 May;30(5):662-70
pubmed: 14630613
Mol Biol Cell. 1998 Sep;9(9):2639-53
pubmed: 9725917
Arterioscler Thromb Vasc Biol. 2001 Nov;21(11):1712-9
pubmed: 11701455
Science. 1998 Jan 23;279(5350):509-14
pubmed: 9438836
Cell Biol Int. 2010 Aug;34(8):815-26
pubmed: 20446922
Ann Intern Med. 2013 Apr 2;158(7):526-34
pubmed: 23546564
Am J Physiol Lung Cell Mol Physiol. 2005 Apr;288(4):L749-60
pubmed: 15591411
Circulation. 2013 Feb 19;127(7):782-90
pubmed: 23334894
J Cell Physiol. 2009 Sep;220(3):716-26
pubmed: 19472214
Trends Cardiovasc Med. 2007 Jul;17(5):151-6
pubmed: 17574122
Physiol Rev. 2006 Jan;86(1):279-367
pubmed: 16371600
Endothelium. 2000;7(4):287-308
pubmed: 11201526
Br J Pharmacol. 2012 Jan;165(1):208-22
pubmed: 21671901
J Clin Invest. 2011 Feb;121(2):628-39
pubmed: 21266780
J Biol Chem. 1993 Sep 5;268(25):18415-8
pubmed: 8360140
Cell Adh Migr. 2014;8(2):108-24
pubmed: 24622613
J Cell Biol. 1995 Apr;129(1):203-17
pubmed: 7698986